Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibrosis, patients were given 15 mg ruxolitinib orally...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Haematologica
Autores principales: Daver, Naval, Cortes, Jorge, Newberry, Kate, Jabbour, Elias, Zhou, Lingsha, Wang, Xuemei, Pierce, Sherry, Kadia, Tapan, Sasaki, Koji, Borthakur, Gautam, Ravandi, Farhad, Pemmaraju, Naveen, Kantarjian, Hagop, Verstovsek, Srdan
Formato: Artigo
Lenguaje:Inglês
Publicado: Ferrata Storti Foundation 2015
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5004422/
https://ncbi.nlm.nih.gov/pubmed/26088933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.126821
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares